Incyte Corporation announced positive results from a Phase 2b study evaluating ruxolitinib cream in patients with atopic dermatitis.
The study, indicated that ruxolitinib cream administered twice daily significantly improved Eczema Area and Severity Index. The results were shared at the 27thEuropean Academy of Dermatology and Venerology Congress in Paris.
Ruxolitinib is best known as Incyte’s blockbuster Jakafi blood disease drug.
“The positive results of this Phase 2 study demonstrate the potential of ruxolitinib cream to offer a novel, effective non-steroidal topical therapy to the millions of patients suffering from AD,” said Steven Stein, M.D., chief medical officer, Incyte. “We look forward to further advancing the True-AD clinical trial program for ruxolitinib cream and initiating Phase 3 registrational trials in this indication to further explore the potential of JAK inhibition to modulate inflammation and itch, and therefore provide much-needed relief to patients with this disease.” .
“There is no cure for AD, and it continues to be a major therapeutic challenge for patients, primary care providers and specialists. Though topical corticosteroids have been a mainstay in treatment of AD for decades, their utility has been limited due to significant side effects associated with long-term use,” said principal investigator of the trial, Brian Kim, assistant professor of Dermatology and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis. “There is an urgent need for new and innovative treatments for patients with this condition, which tends to be chronic. As a physician who treats patients with AD, I am encouraged by the potential of ruxolitinib cream to fill this gap.”
Atopic dermatitis (AD) is a common chronic disease characterized by inflammation of the skin. Approximately 11 million people in the United States have been diagnosed with AD, and the majority have a mild or moderate form of the disease.
Incyte Corporation is a Wilmington-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information, visit www.incyte.com.
